Literature DB >> 10960845

Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.

R Mazzucchelli1, R Montironi, A Santinelli, G Lucarini, A Pugnaloni, G Biagini.   

Abstract

BACKGROUND: Recent studies have demonstrated that angiogenesis is a potent prognostic indicator for patients with prostate cancer (PCa) and have pointed out that the evaluation of vascular endothelial growth factor (VEGF) is useful in assessing the angiogenic phenotype in PCa. The aim of the study was to investigate immunohistochemically the expression of VEGF and its correlation with the pattern of capillary architecture in prostate cancer and high-grade prostatic intraepithelial neoplasia (PIN), in untreated and androgen-ablated patients.
METHODS: Forty-five patients who underwent radical prostatectomy (RP) for localized prostate carcinoma were recruited for this study. The study population included two groups: 35 patients who did not receive chemo-, hormone, or radiation therapy before surgery, and 10 patients who were under complete androgen blockade (CAB) for 3 months at time of surgery. VEGF was examined by immunohistochemistry, and its tissue expression was compared with the pattern of capillary architecture evaluated by immunostaining the endothelial antigen CD34. The relationship of VEGF expression to chromogranin A-positive (e.g., neuroendocrine) cells was investigated.
RESULTS: In normal tissue, the intensity of the VEGF immunoreactivity in the cytoplasm of secretory cells ranged from negative to low. Very few basal cells stained for VEGF. All prostate cancer specimens stained positively, the intensity of the immunoreaction ranging from low to strong and being correlated with the Gleason score. Strongly positive VEGF immunoreactivity was detected in vascular endothelial cells and in stromal cells surrounding blood vessels. Two discrete immunostaining patterns were observed in high-grade PIN. VEGF expression of low-to-moderate intensity was defined as pattern A. The other, characterized by a strong cytoplasmic immunoreaction similar to that of poorly differentiated tumors, was defined as pattern B. The capillary architecture in high-grade PIN with pattern A was similar to the orderly vascular network seen in normal prostates, whereas in the pattern B it had the characteristics of microvessels usually seen in PCa. The degree of vascularization in the stroma adjacent to intensely VEGF-stained cells (neuroendocrine phenotype) was higher than that noted in association with secretory cells. CAB before surgery downregulated the expression of VEGF and decreased the degree of vascularization, except in the cell areas with neuroendocrine (NE) features.
CONCLUSIONS: Our immunohistochemical results indicate that significant levels of VEGF are present in prostate cancer and in a population of PIN lesions, expression being highest in association with NE cells. VEGF expression is downregulated by hormonal manipulation, except in the population of NE cells. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960845     DOI: 10.1002/1097-0045(20000915)45:1<72::aid-pros9>3.0.co;2-u

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  24 in total

1.  Prognostic factors in prostate cancer.

Authors:  R Montironi
Journal:  BMJ       Date:  2001-02-17

2.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

3.  Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.

Authors:  Kylie Graham; Wenliang Li; Bryan R G Williams; Gail Fraizer
Journal:  Gene Expr       Date:  2006

Review 4.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

5.  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Authors:  Vassiliki Tzelepi; Eleni Efstathiou; Sijin Wen; Patricia Troncoso; Maria Karlou; Curtis A Pettaway; Louis L Pisters; Anh Hoang; Christopher J Logothetis; Lance C Pagliaro
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung.

Authors:  Guida Maria Portela-Gomes; Lars Grimelius; Mats Stridsberg; Enrica Bresaola; Giuseppe Viale; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2005-05-20       Impact factor: 4.064

7.  Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?

Authors:  Silvan Boxler; Valentin Djonov; Thomas M Kessler; Ruslan Hlushchuk; Lucas M Bachmann; Ulrike Held; Regula Markwalder; George N Thalmann
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

8.  Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo.

Authors:  Guangbin Zhu; Xinghuan Wang; Zhonghua Yang; Hong Cao; Zhe Meng; Yongzhi Wang; Dong Chen
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

9.  Combined Dynamic Alterations in Urinary VEGF Levels and Tissue ADAM9 Expression as Markers for Lethal Phenotypic Progression of Prostate Cancer.

Authors:  Chen-Chin Pen; Che-Ming Liu; Cho-Chin Lin; Chia-Chen Lin; Teng-Fu Hsieh; Sajni Josson; Yun-Chi He; Leland W K Chung; Keh-Liang Lin; Shian-Ying Sung
Journal:  Chin J Physiol       Date:  2012-12-31       Impact factor: 1.764

10.  Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

Authors:  Jin-Rong Zhou; Lunyin Yu; Luiz F Zerbini; Towia A Libermann; George L Blackburn
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.